Adipokines and their possible role in obesity and type 2 diabetes mellitus
Heading: Endocrinology Article type: Review
Authors: Kuznetsova L.A., Shpakov А.О.
Organization: I. M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Laboratory of Molecular Endocrinology and Neurochemistry
The adipose tissue is the endocrine organ secreting polypeptide factors, such as adipokines, which are involved in the regulation of feeding behavior, the metabolic, endocrine and inflammatory processes and insulin sensitivity. In obesity and type 2 diabetes mellitus (DM2), the production of adipokines and the activity of their signaling pathways are changed, which plays an important role in the relationship between obesity, insulin resistance and DM2. In the review (according the types of obesity) the data on the production of adipokines with diabetogenic (leptin, visfatin, chemerin, vaspin, apelin, resistin) and antidiabetic (adiponectin, omentin) properties by the adipose tissue, as well as the possible role of adipokines in the development of obesity and DM2 were discussed.
Bibliography:
1. Poulos SP, Hausman DB, Hausman GJ. The development and endocrine functions of adipose tissue. Mol Cell Endocrinol 2010; 323(1): 20-34
2. DePaoli AM. 20 years of leptin: leptin in common obesity and associated disorders of metabolism. J Endocrinol 2014; 223 (1):T71-T81
3. Yang J, Kang J, Guan Y. The mechanisms linking adipos-opathy to type 2 diabetes. Front Med 2013; 7 (4): 433-444
4. Amato MC, Pizzolanti G, Torregrossa V, et al. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS One 2014; 9 (3): c91969
5. Abranches MV, Oliveira FC, Conceicao LL, et al. Obesity and diabetes: the link between adipose tissue dysfunction and glucose homeostasis. Nutr Res Rev 2015; 28 (2): 121-132
6. Booth A, Magnuson A, Fouts J, et al. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig2015;21 (1): 57-74
7. Krotkiewski M, Billing-Marczak K. Different types of obesity: Can some types of obesity be protective? Pol Merkur Lekarski 2014; 37 (219): 175-180
8. Bays H. Central obesity as a clinical marker of adiposopa-thy; increased visceral adiposity as a surrogate marker for global fat dysfunction. Curr Opin Endocrinol Diabetes Obes 2014; 21 (5): 345-351
9. Tchernof A, Despres JP Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93 (1): 359-404
10. Farooq R., Amin S, Hayat Bhat M, et al. Type 2 diabetes and metabolic syndrome: adipokine levels and effect of drugs. Gynecol Endocrinol 2017; 33 (1): 75-78
11. Sattar N, Gill JM. Type 2 diabetes as a disease of ectopic fat? ВМС Med 2014; 12: 123-124
12. LukichA, Gavish D, Shargorodsky M. Normal weight diabetic patients versus obese diabetics: relation of overall and abdominal adiposity to vascular health. Cardiovasc Diabetol 2014; 13(1): 141-145
13. Strohle A, Worm N. [Healthy obesity? Why the adiposity paradox is only seemingly paradox]. Med Monatsschr Pharm 2014; 37 (2): 54-64
14. Kyung MC. Sarcopenia and Sarcopenic Obesity. Endocrinol Metab (Seoul) 2013; 28 (2): 86-89
15. Ishii S, Tanaka T, Akishita M, et al. Metabolic Syndrome, Sarcopenia and Role of Sex and Age: Cross-Sectional Analysis of Kashiwa Cohort Study. PLoS One 2014; 9 (11): e112718
16. El-Mesallamy HO, Hamdy NM, Sallam AA. Effect of obesity and glycemic control on serum lipocalins and insulin-like growth factor axis in type 2 diabetic patients. Acta Diabetol 2013; 50 (5): 679-85
17. Geronikolou SA, Pavlopoulou A, Cokkinos D, etal. Inter-actome of Obesity: Obesidome Genetic Obesity, Stress Induced Obesity, Pathogenic Obesity Interaction. Adv Exp Med Biol 2017; 987: 233-241
18. Kaur Y, de Souza RJ, Gibson WT, et al. A systematic review of genetic syndromes with obesity. Obes Rev 2017; 18 (6): 603-634
19. Holmes MV, Pulit SL, Lindgren CM. Genetic and epigen-etic studies of adiposity and cardiometabolic disease. Genome Med 2017; 9(1): 82-85
20. Goodarzi MO. Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. Lancet Diabetes Endocrinol 2017; S2213-8587 (17) 30200-0
21. Shpakov АО, Derkach KV The melanocortin signal system of the hypothalamus and its functional state in type 2 diabetes mellitus and metabolic syndrome. Russian Journal of Physiology 2017; 47 (5): 495-50
22. NoakesTD. So What Comes First: The Obesity or the Insulin Resistance? And Which Is More Important? Clinical Chemistry 2018; 64 (1): 7-9
23. Bondar IA. Advantages, safety and prospects of sita-gliptin application in type 2 diabetes mellitus with chronic kidney disease. Meditsinsky Sovet 2017; (11): 170-175
24. Costa JV, Duarte JS. [Adipose tissue and adipokines]. Acta Med Port 2006; 19 (3): 251-256
25. Fonseca-Alaniz MH, Takada J, Alonso-Vale Ml, et al. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr (Rio J) 2007; 83 (5 Suppl): S192-S203
26. Shpakov АО. The brain leptin signaling system and its functional state in metabolic syndrome and type 2 diabetes mellitus. Journal of Evolutionary Biochemistry and Physiology 2016; 52 (3): 161-176
27. Fujikawa Т, Coppari R. Living without insulin: the role of leptin signaling in the hypothalamus. Front Neurosci 2015; 9: 108
28. Kohara K, Ochi M, Tabara Y, Nagai T, et al. Leptin in sar-copenic visceral obesity: possible link between adipocytes and myocytes. PLoS One 2011; 6 (9): e24633
29. Myers MG, Heymsfield SB, Haft C, et al. Challenges and opportunities of defining clinical leptin resistance. Cell Metab 2012; 15: 150-156
30. Shpakov АО, Derkach KV, Berstein LM. Brain signaling systems in the type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases. Future Science OA (FSO)2015; 1 (3): FS025
31. Park HK, Ahima RS. Leptin signaling. FlOOOPrime Rep 2014; 6: 73
32. Koleva Dl, Orbetzova MM, Atanassova PK. Adipose tissue hormones and appetite and body weight regulators in insulin resistance. Folia Med (Plovdiv) 2013; 55 (1): 25-32
33. Knights AJ, Funnell AP, Pearson RC, et al. Adipokines and insulin action: A sensitive issue. Adipocyte 2014; 3 (2): 88-96
34. Yoo HJ, Choi KM. Adipokines as a novel link between obesity and atherosclerosis. World J Diabetes 2014; 5 (3): 357-363
35. Whitehead JP, Richards AA, Hickman IJ, et al. Adiponec-tin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8 (3): 264-280
36. Escote X, Gomez-Zorita S, Lopez-Yoldi M, et al. Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in Obesity and Diabetes Development. Int J Mol Sci 2017; 18 (8): E1770
37. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008; 15(18): 1851-1862
38. Gao Y, Wang C, Pan T, et al. Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats. Arq Bras Endocrinol Metabol 2014; 58 (1): 42-47
39. Alipour FG, Ashoori MR, Pilehvar-Soltanahmadi Y, et al. An overview on biological functions and emerging therapeutic roles of apelin in diabetes mellitus. Diabetes Metab Syndr 2017: 11 (Suppl2):S919-S923
40. Hu H, He L, Li L, et al. Apelin/APJ system as a therapeutic target in diabetes and its complications. Mol Genet Metab 2016; 119 (1-2): 20-27
41. Kuryszko J, Stawuta P, Sapikowski G. Secretory function of adipose tissue. Pol J Vet Sci 2016; 19 (2): 441-446
42. Goralski KB, McCarthy TC, Hanniman EA, etal. Chemer-in, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007; 282 (38): 28175-28188
43. Heiker JT. Vaspin (serpinA12) in obesity, insulin resistance, and inflammation. J Pept Sci 2014; 20 (5): 299-306
44. Bozkurt Dogan S, Ongoz DF, Balh U, et al. Levels of vaspin and omentin-1 in gingival crevicular fluid as potential markers of inflammation in patients with chronic periodontitis and type 2 diabetes mellitus. J Oral Sci 2016; 58 (3): 379-389
45. Kamble PG, Pereira MJ., Sidibeh CO, et al. Lipocalin 2 produces insulin resistance and can be upregulated by glucocor-ticoids in human adipose tissue. Mol Cell Endocrinol 2016; 427: 124-132
46. Guilherme A, Virbasius JV, Puri V, et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9 (5): 367-377
47. Brocker C, Thompson D, Matsumoto A, et al. Evolutionary divergence and functions of human interleukin (IL) gene family. Hum Genomics 2010; 5 (1): 1 -30
48. Katagiri H, Yamada T, Oka Y Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 2007; 101: 27-39.
Attachment | Size |
---|---|
2018_2_201-206.pdf | 322.7 KB |